Pathstone Holdings, LLC Halozyme Therapeutics, Inc. Transaction History
Pathstone Holdings, LLC
- $22.3 Billion
- Q3 2024
A detailed history of Pathstone Holdings, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 9,389 shares of HALO stock, worth $550,289. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,389
Previous 10,806
13.11%
Holding current value
$550,289
Previous $565,000
4.96%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
531Shares Held
122MCall Options Held
199KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$756 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$389 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$238 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$200 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.16B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...